Search results
Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.
Feb 8, 2022 · Juno veterans went on to start or fill leadership positions at Sana Biotechnology, Lyell Immunopharma, Umoja Biopharma, Shape Therapeutics, GentiBio, Eliem Therapeutics, Genemod, Century...
Jan 5, 2016 · Juno is a promising immunotherapy company with huge commercial potential. While CAR-T therapy is well established, carrying out this type of treatment is labor intensive and will introduce...
- Bay Area Biotech
Feb 5, 2021 · FDA approves Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed ...
Nov 2, 2017 · Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer.
Nov 1, 2017 · Shares in Juno Therapeutics jumped by more than 8 per cent on Wednesday after the release of clinical trial data ahead of a closely-watched medical meeting this weekend.
Jan 22, 2018 · Juno is a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications.
